表紙
市場調査レポート

関節リウマチ:パイプライン製品の分析

Rheumatoid Arthritis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232779
出版日 ページ情報 英文 1143 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
関節リウマチ:パイプライン製品の分析 Rheumatoid Arthritis - Pipeline Review, H1 2016
出版日: 2016年06月28日 ページ情報: 英文 1143 Pages
概要

関節リウマチは慢性的自己免疫疾患で、最終的には奇形の原因となる骨の破壊につながります。体の免疫システムは自己と異物を識別することができず、異常な形で働くことがあります。関節はまず最初に影響を受け、こわばり、炎症に発展していきます。更に、この疾患は他の器官にも影響を及ぼします。 関節リウマチは遺伝的あるいは他の特殊な環境的要因によって引き起こされます。女性は特にかかりやすく、放置しておくと障害を含め、様々な合併症を引き起こします。

当レポートでは、関節リウマチの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

関節リウマチの概要

治療薬の開発

関節リウマチ:企業で開発中の治療薬

関節リウマチ:大学/機関で研究中の治療薬

関節リウマチ:パイプライン製品の概況

関節リウマチ:企業で開発中の製品

関節リウマチ:大学/機関で研究中の製品

関節リウマチの治療薬開発に従事している企業

関節リウマチ:治療薬の評価

薬剤プロファイル

関節リウマチ:休止中のプロジェクト

関節リウマチ:開発が中止された製品

関節リウマチ:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7957IDB

Summary

Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H1 2016', provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
  • The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects
  • The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Rheumatoid Arthritis Overview
  • Therapeutics Development
  • Rheumatoid Arthritis - Therapeutics under Development by Companies
  • Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes
  • Rheumatoid Arthritis - Pipeline Products Glance
  • Rheumatoid Arthritis - Products under Development by Companies
  • Rheumatoid Arthritis - Products under Investigation by Universities/Institutes
  • Rheumatoid Arthritis - Companies Involved in Therapeutics Development
  • Rheumatoid Arthritis - Therapeutics Assessment
  • Drug Profiles
  • Rheumatoid Arthritis - Dormant Projects
  • Rheumatoid Arthritis - Discontinued Products
  • Rheumatoid Arthritis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Rheumatoid Arthritis, H1 2016
  • Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Rheumatoid Arthritis - Pipeline by 3SBio Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H1 2016
  • Rheumatoid Arthritis - Pipeline by 4SC AG, H1 2016
  • Rheumatoid Arthritis - Pipeline by AB Science SA, H1 2016
  • Rheumatoid Arthritis - Pipeline by AB2 Bio Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by AbbVie Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Ablynx NV, H1 2016
  • Rheumatoid Arthritis - Pipeline by ACEA Biosciences, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd, H1 2016
  • Rheumatoid Arthritis - Pipeline by AlphaMab Co., Ltd, H1 2016
  • Rheumatoid Arthritis - Pipeline by Alteogen Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Amgen Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Amura Holdings Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corporation, H1 2016
  • Rheumatoid Arthritis - Pipeline by ARA Healthcare Pvt. Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Rheumatoid Arthritis - Pipeline by Arthrogen BV, H1 2016
  • Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp., H1 2016
  • Rheumatoid Arthritis - Pipeline by Asana BioSciences, LLC, H1 2016
  • Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H1 2016
  • Rheumatoid Arthritis - Pipeline by Avexxin AS, H1 2016
  • Rheumatoid Arthritis - Pipeline by Axxam SpA, H1 2016
  • Rheumatoid Arthritis - Pipeline by BCN Peptides, S.A., H1 2016
  • Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by BIOCAD, H1 2016
  • Rheumatoid Arthritis - Pipeline by Biocon Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by BioLingus AG, H1 2016
  • Rheumatoid Arthritis - Pipeline by BioLite, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Bionovis SA, H1 2016
  • Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Bird Rock Bio, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Rheumatoid Arthritis - Pipeline by Bone Medical Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by CEL-SCI Corporation, H1 2016
  • Rheumatoid Arthritis - Pipeline by Celgene Corporation, H1 2016
  • Rheumatoid Arthritis - Pipeline by Cellceutix Corporation, H1 2016
  • Rheumatoid Arthritis - Pipeline by Celltrion, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by ChemoCentryx, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H1 2016
  • Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp., H1 2016
  • Rheumatoid Arthritis - Pipeline by CLL Pharma, H1 2016
  • Rheumatoid Arthritis - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Commence Bio, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Compugen Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Confluence Life Sciences, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by CSL Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H1 2016
  • Rheumatoid Arthritis - Pipeline by Domainex Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Eisai Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H1 2016
  • Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H1 2016
  • Rheumatoid Arthritis - Pipeline by Endocyte, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Galapagos NV, H1 2016
  • Rheumatoid Arthritis - Pipeline by Gene Techno Science Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Genentech, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Genosco, H1 2016
  • Rheumatoid Arthritis - Pipeline by Gilead Sciences, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H1 2016
  • Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Handok Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H1 2016
  • Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corporation, H1 2016
  • Rheumatoid Arthritis - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Hetero Drugs Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by HitGen LTD, H1 2016
  • Rheumatoid Arthritis - Pipeline by Huabo Biopharm Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Idogen AB, H1 2016
  • Rheumatoid Arthritis - Pipeline by Immune Response BioPharma, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Immungenetics AG, H1 2016
  • Rheumatoid Arthritis - Pipeline by ImmunoFrontier, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Innate Pharma S.A., H1 2016
  • Rheumatoid Arthritis - Pipeline by Innovent Biologics, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by ISU ABXIS Co.,Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by JHL Biotech, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H1 2016
  • Rheumatoid Arthritis - Pipeline by Jyant Technologies, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Rheumatoid Arthritis - Pipeline by KAHR medical Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Kang Stem Biotech Co., Ltd., H1 2016
  • Rheumatoid Arthritis - Pipeline by Karus Therapeutics Limited, H1 2016
  • Rheumatoid Arthritis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Kezar Life Sciences, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Kineta, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by Lead Pharma Holding B.V., H1 2016
  • Rheumatoid Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016
  • Rheumatoid Arthritis - Pipeline by LG Life Science LTD., H1 2016

List of Figures

  • Number of Products under Development for Rheumatoid Arthritis, H1 2016
  • Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top